Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA4 | P22748 | 5/20 | 0.38 |
| ▸ | CA5A | P35218 | 5/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA7 | P43166 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17305220 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1SRCCA2CA4 | |
| SCHEMBL27836558 | 0.79 | SRC (0.52) | L3MBTL1TDP1SRCKDM4EMEN1 | |
| SCHEMBL2303782 | 0.79 | SRC (0.52) | L3MBTL1TDP1SRCKDM4EMEN1 | |
| SCHEMBL80417 | 0.79 | SRC (0.52) | L3MBTL1TDP1SRCKDM4EMEN1 | |
| SCHEMBL873578 | 0.78 | SRC (0.55) | L3MBTL1TDP1SRCCA2CA4 | |
| SCHEMBL9911203 | 0.76 | SRC (0.48) | L3MBTL1TDP1SRCKDM4EMEN1 | |
| SCHEMBL25883278 | 0.76 | SRC (0.48) | L3MBTL1TDP1SRCKDM4EMEN1 | |
| SCHEMBL27881894 | 0.75 | SRC (0.47) | L3MBTL1TDP1SRCKDM4EMEN1 | |
| SCHEMBL8587398 | 0.74 | L3MBTL1 (0.53) | L3MBTL1TDP1SRCCA2CA4 | |
| Phosphoric Acid SCHEMBL29974621 | 0.74 | SRC (0.46) | L3MBTL1TDP1SRCCA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948453-B1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9556180-B2 | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS PHARMA AG (CH) | 2015-12-10 | — | — | US | disclosed |
| EP-2948453-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | Novartis AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014115080-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| CN-101321736-B | To M1Compounds with receptor activity and their use in medicine | GLAXO GROUP LTD | 2012-04-04 | — | — | CN | disclosed |
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| CN-101321736-A | To M1Compounds with receptor activity and their use in medicine | GLAXO GROUP LTD (GB) | 2008-12-10 | — | — | CN | disclosed |
| US-5698569-A | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5622949-A | AIDS THERAPY | G. D. SEARLE & CO. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620977-A | HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5475013-A | Inhibit human immunodeficiency virus protease | MONSANTO COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| EP-0047620-B1 | ARYL DIAZABICYCLYL AMIDES, A PROCESS FOR THEIR PREPARATION AND USE | BEECHAM GROUP PLC (GB) | 1985-03-13 | — | — | EP | disclosed |
| EP-0047620-A1 | Aryl diazabicyclyl amides, a process for their preparation and use | BEECHAM GROUP PLC (GB) | 1982-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | TP53, MDM4, MDM2 | L3MBTL1 1881/4885TDP1 124/4885SRC 2049/4885 |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | L3MBTL1 2814/4885TDP1 1420/4885SRC 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.